Long Term Follow-up on Menkes Disease Patients

Menkes Disease Clinical Trial

Official title:
Long Term Follow-Up and Collection of Historical Control Data on Menkes Disease Patients

Status Enrolling by invitation

Clinical Trial Summary

This study will collect long term follow-up data regarding overall survival and neurological parameters from patients previously identified and/or enrolled in Protocols 09-CH-0059 and 90-CH0149 and Historical Control data on Menkes disease patients.

Clinical Trial Description

Primary Objective: 1. To provide additional clinical and safety data on long term following administration of Copper Histidinate treatment in patients treated with Copper Histidinate under Protocols 09-CH-0059 and 90-CH0149 and untreated patients previously identified and/or enrolled in Protocol 09-CH-0059. 2. To provide additional Historical Control data on Menkes disease patients. ;

Study Design

Related Conditions & MeSH terms

Menkes Disease

Clinical Trial Details

NCT number	NCT04337684
Study type	Observational
Source	Cyprium Therapeutics, Inc.
Contact
Status	Enrolling by invitation
Phase
Start date	December 1, 2019
Completion date	December 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05687474` - Baby Detect : Genomic Newborn Screening
Enrolling by invitation	`NCT03655223` - Early Check: Expanded Screening in Newborns
Recruiting	`NCT04977388` - NORTHERA (DROXIDOPA) for Dysautonomia in Adult Survivors of Menkes Disease and Occipital Horn Syndrome	Phase 1/Phase 2
Completed	`NCT00811785` - Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency	Phase 3
Available	`NCT04074512` - Copper Histidinate Treatment for Menkes Disease